Expertise in
22
conditions

Dr. Melissa J. Alsina

Internal Medicine
Moffitt Magnolia Campus
12902 Usf Magnolia Dr, 
Tampa, FL 
Accepting New Patients
Offers Telehealth
Expertise in
22
conditions
Moffitt Magnolia Campus
12902 Usf Magnolia Dr, 
Tampa, FL 

Overview

Melissa Alsina is a primary care provider, practicing in Internal Medicine in Tampa, Florida.

Dr. Alsina is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Plasmacytoma, Bone Marrow Aspiration, and Colonoscopy.

He is actively involved in clinical research, co-authoring 108 peer reviewed articles and participating in 16 clinical trials. Dr. Alsina is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetLife
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Moffitt Magnolia Campus
12902 Usf Magnolia Dr, Tampa, FL 33612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

Phase II Study of Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
Phase II Study of Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
Enrollment Status: Completed
Publish Date: August 20, 2026
Intervention Type: Drug
Study Drugs: Daratumumab Injection, Dexamethasone Oral, Lenalidomide Pill, Bortezomib Injection
Study Phase: Phase 2
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease
Enrollment Status: Completed
Publish Date: April 02, 2026
Intervention Type: Drug
Study Drugs: BMS-986004, Sirolimus, Tacrolimus
Study Phase: Phase 1
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
Enrollment Status: Completed
Publish Date: April 02, 2026
Intervention Type: Drug, Procedure
Study Drugs: Pacritinib, Sirolimus, Tacrolimus
Study Phase: Phase 1/Phase 2
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
Enrollment Status: Active_not_recruiting
Publish Date: March 02, 2026
Intervention Type: Drug, Other
Phase 1/1b Trial of Donor γδ T--Cell Infusion for Treatment of Patients With Acute Myeloid Leukemia at High Risk of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Phase 1/1b Trial of Donor γδ T--Cell Infusion for Treatment of Patients With Acute Myeloid Leukemia at High Risk of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Active_not_recruiting
Publish Date: February 09, 2026
Intervention Type: Biological
Study Drug: Gamma Delta T-Cell Infusion
Study Phase: Phase 1
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: December 11, 2025
Intervention Type: Radiation, Drug
Study Drugs: Fludarabine, Melphalan
Study Phase: Phase 2
Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Subjects With High Risk Smoldering Multiple Myeloma (SMM)
Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Subjects With High Risk Smoldering Multiple Myeloma (SMM)
Enrollment Status: Active_not_recruiting
Publish Date: December 12, 2023
Intervention Type: Drug
Study Drugs: Carfilzomib, Lenalidomide, Daratumumab, Dexamethasone
Study Phase: Phase 2
Investigator-Initiated Phase I/II Clinical Trial of Selinexor (KPT-330) and Liposomal Doxorubicin for Relapsed and Refractory Multiple Myeloma
Investigator-Initiated Phase I/II Clinical Trial of Selinexor (KPT-330) and Liposomal Doxorubicin for Relapsed and Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: January 04, 2023
Intervention Type: Drug
Study Drugs: Selinexor, Liposomal Doxorubicin, Dexamethasone
Study Phase: Phase 1/Phase 2
Evaluating the Safety and Biological Activity of a Dendritic Cell Survivin Vaccine in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplantation
Evaluating the Safety and Biological Activity of a Dendritic Cell Survivin Vaccine in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: November 14, 2022
Intervention Type: Biological, Drug, Procedure
Study Drugs: Survivin Vaccine, Prevnar 13, Granulocyte-colony Stimulating Factor
Study Phase: Early Phase 1
Phase 1/2 Investigator Sponsored Study of Selinexor in Combination With High-Dose Melphalan Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Phase 1/2 Investigator Sponsored Study of Selinexor in Combination With High-Dose Melphalan Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Enrollment Status: Completed
Publish Date: November 04, 2022
Intervention Type: Drug, Procedure
Study Drugs: Selinexor, Melphalan, Dexamethasone, Fosaprepitant
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

108 Total Publications

Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis.
Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis.
Journal: Blood advances
Published: April 08, 2026
Similar Doctors
Expertise in
24
conditions
Dr. Frederick L. Locke
Internal Medicine
Expertise in
24
conditions
Dr. Frederick L. Locke
Internal Medicine

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-692-4252
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Frederick Locke is a primary care provider, practicing in Internal Medicine in Tampa, Florida. Dr. Locke is highly rated in 24 conditions, according to our data. His clinical expertise encompasses B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Graft, and Bone Marrow Aspiration. Dr. Locke is currently accepting new patients.

Expertise in
41
conditions
Dr. Taiga Nishihori
Internal Medicine
Expertise in
41
conditions
Dr. Taiga Nishihori
Internal Medicine
Before you request

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-723-4775
Languages Spoken:
English, Japanese
See accepted insurances
Accepting New Patients
Offers Telehealth

Taiga Nishihori is a primary care provider, practicing in Internal Medicine in Tampa, Florida. Dr. Nishihori is highly rated in 41 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Bone Graft, and Bone Marrow Aspiration. Dr. Nishihori is currently accepting new patients.

Expertise in
41
conditions
Dr. Andrew T. Kuykendall
Hematology Oncology | Internal Medicine
Expertise in
41
conditions
Dr. Andrew T. Kuykendall
Hematology Oncology | Internal Medicine
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-701-3769
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Kuykendall is an Internal Medicine provider practicing medicine in Tampa, Florida. Dr. Kuykendall is highly rated in 41 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Polycythemia Vera, Myeloproliferative Neoplasms (MPN), Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration. Dr. Kuykendall is currently accepting new patients.

Frequently Asked Questions about Dr. Melissa J. Alsina

How do I make an appointment with Dr. Melissa J. Alsina?

You can book an appointment with Dr. Melissa J. Alsina by calling their office at 888-663-3488. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Melissa J. Alsina a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Melissa J. Alsina is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Melissa J. Alsina specialize in?

While Dr. Melissa J. Alsina is a Internal Medicine, they have specific expertise in Multiple Myeloma, Smoldering Multiple Myeloma, and Plasmacytoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Melissa J. Alsina participate in research or clinical trials?

Yes. Dr. Melissa J. Alsina has published 108 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Melissa J. Alsina's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Melissa J. Alsina accept my insurance?

Dr. Melissa J. Alsina accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 888-663-3488 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Alsina's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 10 Advanced Conditions
View All 92 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile